Berry Genomics
Berry Genomics is a Beijing-based, publicly traded Chinese clinical genomics company that develops NIPT, carrier screening, and clinical-grade long-read sequencing products — including the NMPA-approved PacBio Sequel II CNDx system and thalassemia assay — serving healthcare providers and public health screening programs in China.
- Company typePublic
- Founded2010
- HeadquartersBeijing, China
- Headcount1,001–5,000
- GTM typeB2B and B2C
- OfferingServices
What Berry Genomics does
Berry Genomics is a Beijing-based, publicly traded (szse:000710) clinical genomics company founded in 2010, operating with 1,001–5,000 employees and headquartered in China. The company's core business is developing and commercializing genetic testing products for clinical and public health applications in China, with a portfolio that includes non-invasive prenatal testing (NIPT), carrier screening, and — as of November 2025 — clinical-grade long-read sequencing via the PacBio Sequel II CNDx system and a thalassemia assay approved by China's NMPA. The underlying technology is single-molecule real-time (SMRT) sequencing, supplied through a technology partnership with Pacific Biosciences (PacBio), which Berry Genomics leverages to pursue high-accuracy comprehensive genomic analysis for complex genetic disorders such as thalassemia. The Sequel II CNDx approval represents the first clinical-grade long-read sequencer approval in China, giving Berry Genomics a regulatory first-mover position in this clinical category.
Berry Genomics firmographics
Firmographics- Name
- Berry Genomics
- Legal name
- Berry Genomics
- Website
- https://berrygenomics.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Berry Genomics is a Beijing-based, publicly traded Chinese clinical genomics company that develops NIPT, carrier screening, and clinical-grade long-read sequencing products — including the NMPA-approved PacBio Sequel II CNDx system and thalassemia assay — serving healthcare providers and public health screening programs in China.
- Ownership category
- akta.pro rank
Berry Genomics industry classification
Industry- Product category
- Clinical Genomics and Genetic Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Prenatal Testing Laboratories (HLAFAMAH)
- akta.pro secondary industries
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
Keywords
Where Berry Genomics is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Markets served
Berry Genomics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Berry Genomics product offering
Product offeringCore offering
Berry Genomics develops and commercializes clinical genomic testing products and services, including non-invasive prenatal testing (NIPT), carrier screening, and clinical diagnostics for genetic disorders. Its portfolio includes the PacBio Sequel II CNDx long-read sequencer (the first NMPA-approved clinical-grade long-read sequencer in China) and diagnostic assays such as the thalassemia assay, all powered by single-molecule real-time (SMRT) sequencing technology.
Product overview
Berry Genomics is a genetic testing company specializing in non-invasive prenatal testing (NIPT), carrier screening, and clinical genomic diagnostics. The company's portfolio centers on the PacBio Sequel II CNDx system (a long-read sequencing platform) and associated diagnostic assays including a thalassemia assay, all powered by single-molecule real-time (SMRT) sequencing technology. Berry Genomics operates as a subsidiary unit with focus on next-generation gene sequencing for clinical applications in China, having achieved the first regulatory approval for clinical-grade long-read sequencing in the country.
Differentiator
Problem solved
Functional benefit
Products and services
- Sequel II CNDx System A clinical-grade long-read sequencer developed by Pacific Biosciences in partnership with Berry Genomics. It is the first NMPA-approved clinical-grade long-read sequencer in China, enabling high-accuracy comprehensive genomic testing for genetic disorders such as thalassemia.
- Thalassemia Assay A diagnostic assay approved alongside the Sequel II CNDx system for detecting thalassemia and other genetic disorders. The assay utilizes single-molecule real-time (SMRT) sequencing technology to improve diagnosis of genetic diseases.
- Non-Invasive Prenatal Testing (NIPT) Non-invasive prenatal testing services offered by Berry Genomics as part of its clinical genomics portfolio, used by expectant mothers and their obstetricians to detect fetal chromosomal abnormalities during pregnancy.
- Carrier Screening Clinical genetic carrier screening services offered by Berry Genomics, allowing prospective parents to assess their risk of passing inherited genetic conditions to their children.
- Clinical Genomic Diagnostics Clinical-grade genomic diagnostic services for genetic disorders leveraging Berry Genomics' long-read sequencing platform and diagnostic assays, offered through Chinese hospitals and clinical laboratories.
Companies that use Berry Genomics
Customer profileSegments2 records
Ideal customer profiles3 records
Berry Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Berry Genomics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Pacific Biosciences (PacBio)coreBerry Genomics partnered with PacBio to achieve regulatory approval for the Sequel II CNDx system from China's NMPA. This marked the first regulatory clearance of a clinical-grade long-read sequencer in China. The partnership enables Berry Genomics to offer PacBio's HiFi sequencing technology for complex genetic testing, particularly for diseases like thalassemia. The approval allows Chinese clinicians to perform high-accuracy comprehensive genomic analysis in clinical settings.
Recent moves6 records
Expansion highlights5 records
Berry Genomics competitors and assessment
Company assessmentBroad incumbents
- BGI Genomics: BGI is China's largest genomics and clinical sequencing services provider, offering NIPT, rare-disease panels, and population genomics. It is the dominant incumbent competing against Berry Genomics across prenatal screening and clinical sequencing in China.
- KingMed Diagnostics: KingMed is a leading independent clinical laboratory chain in China providing specialty genetic, pathology, and molecular diagnostic services. It is a broad incumbent across clinical testing including the segments Berry Genomics targets.
Direct peers
- Annoroad Genomics: Annoroad is a Chinese NGS-based clinical diagnostics company with NIPT, reproductive health, and tumor testing offerings. It competes directly with Berry Genomics in China's prenatal and clinical sequencing market.
- Da An Gene (Kingstar): Da An Gene operates one of China's largest clinical diagnostic laboratory networks with broad molecular and genetic testing menus, including prenatal and infectious disease testing — direct overlap with Berry Genomics' clinical services.
- Natera: Natera is a US-listed reproductive and oncology genetics testing company with leading NIPT and carrier screening franchises. It is the most direct international comparability point for Berry Genomics' prenatal and carrier screening business model.
- Myriad Genetics: Myriad is an established US genetic testing company with carrier screening, prenatal, and hereditary cancer tests. It serves as a direct business-model peer for clinical germline genetic testing services.
- NeoGenomics: NeoGenomics operates clinical genetic and oncology testing labs serving hospitals and physicians in the US and internationally. It is comparable to Berry Genomics as a clinical genomics services provider serving healthcare providers.
Others
- Pacific Biosciences (PacBio): PacBio is the developer of SMRT/HiFi long-read sequencing and the technology partner behind Berry Genomics' Sequel II CNDx system. While not a commercial competitor, PacBio is materially comparable because it sets the technology roadmap Berry Genomics' clinical long-read franchise depends on.
Emerging players
- QIAGEN: QIAGEN supplies molecular diagnostic sample technologies, PCR/NGS reagents, and bioinformatics used in clinical genetic testing labs. It is an emerging player in the same sample-to-result workflows Berry Genomics' clinical sequencing business relies upon.
- Oxford Nanopore Technologies: Oxford Nanopore develops long-read nanopore sequencing platforms used in clinical and research genomics. It is comparable to Berry Genomics' PacBio-based long-read offering as a competing long-read technology approach entering clinical use globally.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Berry Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Berry Genomics leadership team
Management profileNumber of profiles
Profiles4 records
Berry Genomics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Berry Genomics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Berry Genomics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Berry Genomics
What does Berry Genomics do?
Berry Genomics develops and commercializes clinical genomic testing products and services, including non-invasive prenatal testing (NIPT), carrier screening, and clinical diagnostics for genetic disorders. Its portfolio includes the PacBio Sequel II CNDx long-read sequencer (the first NMPA-approved clinical-grade long-read sequencer in China) and diagnostic assays such as the thalassemia assay, all powered by single-molecule real-time (SMRT) sequencing technology.
Is Berry Genomics a public or private company?
Berry Genomics is a public company. It is classified as public and is currently operating.
When was Berry Genomics founded?
Berry Genomics was founded in 2010. It employs 1,001 to 5,000 people.
Where is Berry Genomics based?
Berry Genomics is headquartered in Beijing, China, in the Asia region.
Who are Berry Genomics's main competitors?
Broad incumbents on record are BGI Genomics and KingMed Diagnostics. Direct peers are Annoroad Genomics, Da An Gene (Kingstar), Natera, Myriad Genetics and NeoGenomics. Pacific Biosciences (PacBio) is listed as an others. Emerging players are QIAGEN and Oxford Nanopore Technologies.
Does Berry Genomics have an API?
No public API is recorded for Berry Genomics.
What industry is Berry Genomics in?
Berry Genomics's product category is Clinical Genomics and Genetic Diagnostics. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621511 and its SIC code is 2835.